drugset / Trial / NCT04965636
Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.
Timeline
- Start
- 2022-07-14
- Primary completion
- 2025-10-28
- Completion
- 2025-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mepolizumab | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | Mepolizumab | Monoclonal antibody | 300 mg | Subcutaneous |